Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: The SEVEN-UP study

American Journal of Ophthalmology

Volumn 159, Issue 5, 2015, Pages 915-924.e2

  Bhisitkul, Robert B ^a   Mendes, Thais S ^a   Rofagha, Soraya ^a   Enanoria, Wayne ^a   Boyer, David S ^b   Sadda, SriniVas R ^c   Zhang, Kang ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; DISEASE COURSE; FOLLOW UP; HUMAN; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; VISUAL ACUITY; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; GEOGRAPHIC ATROPHY; INCIDENCE; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE PROGRESSION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; GEOGRAPHIC ATROPHY; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84927567257     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2015.01.032     Document Type: Article

References (37)

1. P.J. Rosenfeld, D.M. Brown, and J.S. Heier et al. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1419 1431
2. D.M. Brown, M. Michels, and P.K. Kaiser et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 1 2009 57 65
3. D.F. Martin, M.G. Maguire, and S.L. Fine et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 7 2012 1388 1398
4. J.S. Heier, D.M. Brown, and V. Chong et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration Ophthalmology 119 12 2012 2537 2548
5. U. Chakravarthy, S.P. Harding, and C.A. Rogers et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial Lancet 382 9900 2013 1258 1267
6. B.G. Busbee, A.C. Ho, and D.M. Brown et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration Ophthalmology 120 5 2013 1046 1056
7. U. Schmidt-Erfurth, P.K. Kaiser, and J.F. Korobelnik et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies Ophthalmology 121 1 2014 193 201
8. R. Dunavoelgyi, S. Sacu, and K. Eibenberger et al. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results Retina 32 8 2012 1471 1479
9. S. Rofagha, R.B. Bhisitkul, and D.S. Boyer et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP) Ophthalmology 120 11 2013 2292 2299
10. D.M. Brown, P.K. Kaiser, and M. Michels et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1432 1444
11. M.A. Singer, C.C. Awh, and S. Sadda et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration Ophthalmology 119 6 2012 1175 1183
12. P.J. Rosenfeld, H. Shapiro, and L. Tuomi et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials Ophthalmology 118 3 2011 523 530
13. J.E. Grunwald, E. Daniel, and J. Huang et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials Ophthalmology 121 3 2014 150 161
14. G.J. Jaffe, D.F. Martin, and C.A. Toth et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials Ophthalmology 120 9 2013 1860 1870
15. R. Channa, S. Rafaay, and S. Bagheri et al. Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial factor-treated eyes Am J Ophthalmol 159 1 2015 9 19
16. R. Klein, C.-F. Chou, and B.E. Klein et al. Prevalence of age-related macular degeneration in the US population Arch Ophthalmol 129 1 2011 75 80
17. C. Schütze, C. Ahlers, and S. Sacu et al. Performance of OCT segmentation procedures to assess morphology and extension in geographic atrophy Acta Ophthalmol 89 3 2011 235 240
18. R. Forte, G. Querques, and L. Querques et al. Multimodal evaluation of foveal sparing in patients with geographicatrophy due to age-related macular degeneration Retina 33 3 2013 482 489
19. A.S. Lindblad, P.C. Lloyd, and T.E. Clemons et al. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26 Arch Ophthalmol 127 9 2009 1168 1174
20. S. Lee, T.T. Chen, and C.L. Barber et al. Autocrine VEGF signaling is required for vascular homeostasis Cell 130 4 2007 691 703
21. M. Saint-Geniez, T. Kurihara, and E. Sekiyama et al. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris Proc Natl Acad Sci U S A 106 44 2009 18751 18756
22. S. Peters, P. Heiduschka, and S. Julien et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab Am J Ophthalmol 143 6 2007 995 1002
23. R.H. Foxton, A. Finkelstein, and S. Vijay et al. VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma Am J Pathol 182 4 2013 1379 1390
24. K. Nishijima, Y.S. Ng, and L. Zhong et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury Am J Pathol 171 1 2007 53 67
25. T. Hao, and P. Rockwell Signaling through the vascular endothelial growth factor receptor VEGFR-2 protects hippocampal neurons from mitochondrial dysfunction and oxidative stress Free Radic Biol Med 63 2013 421 431
26. A. Miki, K. Miki, and S. Ueno et al. Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells J Cell Physiol 224 1 2010 262 272
27. G. Querques, N. Massamba, and F. Coscas et al. Choroidal neovascularisation complicating geographic atrophy in age-related macular degeneration Br J Ophthalmol 96 12 2012 1479 1483
28. D.M. Brown, Q.D. Nguyen, and D.M. Marcus et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE Ophthalmology 120 10 2013 2013 2022
29. D.M. Brown, P.A. Campochiaro, and R.B. Bhisitkul et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study Ophthalmology 118 8 2011 1594 1602
30. J.S. Heier, W.L. Clark, and D.S. Boyer et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: Two-year results from the COPERNICUS study Ophthalmology 121 7 2014 1414 1420
31. J.S. Heier, P.A. Campochiaro, and L. Yau et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial Ophthalmology 119 4 2012 802 809
32. P.A. Campochiaro, R. Sophie, and J. Pearlman et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study Ophthalmology 121 1 2014 209 219
33. M.J. Elman, N.M. Bressler, and H. Qin et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 118 4 2011 609 614
34. D.V. Do, Q.D. Nguyen, and A.A. Khwaja et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged treatment JAMA Ophthalmol 131 2 2014 139 145
35. U. Schmidt-Erfurth, G.E. Lang, and F.G. Holz et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: The RESTORE Extension Study Ophthalmology 121 5 2014 1045 1053
36. D.V. Do, Q.D. Nguyen, and D. Boyer et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema Ophthalmology 119 8 2012 1658 1665
37. Macular Photocoagulation Study Group Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial Arch Ophthalmol 109 9 1991 1220 1231